|
DE3360633D1
(en)
*
|
1982-02-12 |
1985-10-03 |
Unitika Ltd |
Anti-cancer device
|
|
US4389393A
(en)
*
|
1982-03-26 |
1983-06-21 |
Forest Laboratories, Inc. |
Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
|
|
DE3435325A1
(de)
*
|
1983-04-09 |
1986-04-17 |
Nikken Chemicals Co., Ltd., Tokio/Tokyo |
Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
|
|
US4591500A
(en)
*
|
1983-04-25 |
1986-05-27 |
Microencapsulation S.A. |
Tablet having the shape of a capsule, process and device for its preparation
|
|
US4571333A
(en)
*
|
1983-06-14 |
1986-02-18 |
Syntex (U.S.A.) Inc. |
Controlled release naproxen and naproxen sodium tablets
|
|
JPH0662404B2
(ja)
*
|
1983-06-14 |
1994-08-17 |
シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド |
制御放出性ナプロキセンおよびナプロキセンナトリウム錠
|
|
IL72381A
(en)
*
|
1983-07-20 |
1988-03-31 |
Sanofi Sa |
Pharmaceutical composition based on valproic acid
|
|
JPS6038322A
(ja)
*
|
1983-08-11 |
1985-02-27 |
Fujisawa Pharmaceut Co Ltd |
ジヒドロピリジンａ物質含有易溶性固形製剤
|
|
US4680323A
(en)
*
|
1983-12-01 |
1987-07-14 |
Hans Lowey |
Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
|
|
FR2556965B1
(fr)
*
|
1983-12-21 |
1986-08-22 |
Rhone Poulenc Sante |
Nouvelle forme galenique du ketoprofene a liberation controlee
|
|
GB2154874B
(en)
*
|
1984-02-29 |
1987-11-04 |
Sandoz Ltd |
Bromoscriptine compositions
|
|
CH666406A5
(de)
*
|
1984-02-29 |
1988-07-29 |
Sandoz Ag |
Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
|
|
US4795327A
(en)
*
|
1984-03-26 |
1989-01-03 |
Forest Laboratories, Inc. |
Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
|
|
US4540566A
(en)
*
|
1984-04-02 |
1985-09-10 |
Forest Laboratories, Inc. |
Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
|
|
GB8414220D0
(en)
*
|
1984-06-04 |
1984-07-11 |
Sterwin Ag |
Medicaments in unit dose form
|
|
US4532244A
(en)
*
|
1984-09-06 |
1985-07-30 |
Innes Margaret N |
Method of treating migraine headaches
|
|
AU592065B2
(en)
*
|
1984-10-09 |
1990-01-04 |
Dow Chemical Company, The |
Sustained release dosage form based on highly plasticized cellulose ether gels
|
|
US4695464A
(en)
*
|
1984-10-09 |
1987-09-22 |
The Dow Chemical Company |
Sustained release dosage form based on highly plasticized cellulose ether gels
|
|
US4678516A
(en)
*
|
1984-10-09 |
1987-07-07 |
The Dow Chemical Company |
Sustained release dosage form based on highly plasticized cellulose ether gels
|
|
US4639458A
(en)
*
|
1985-01-22 |
1987-01-27 |
Merck & Co., Inc. |
Tablet and formulation
|
|
AT388101B
(de)
*
|
1985-02-05 |
1989-05-10 |
Sandoz Ag |
Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur oralen verabreichung mit kontrollierter wirkstofffreisetzung
|
|
HU195729B
(en)
*
|
1985-02-05 |
1988-07-28 |
Sandoz Ag |
Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides
|
|
AU598751B2
(en)
*
|
1985-02-07 |
1990-07-05 |
Novartis Ag |
Pharmaceutical formulations with controlled release of the active substance
|
|
US4695591A
(en)
*
|
1985-03-29 |
1987-09-22 |
Schering Corporation |
Controlled release dosage forms comprising hydroxypropylmethylcellulose
|
|
US4601894A
(en)
*
|
1985-03-29 |
1986-07-22 |
Schering Corporation |
Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
|
|
US4657757A
(en)
*
|
1985-03-29 |
1987-04-14 |
Schering Corporation |
Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
|
|
US4885173A
(en)
*
|
1985-05-01 |
1989-12-05 |
University Of Utah |
Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
|
|
EP0227814A1
(en)
*
|
1985-07-02 |
1987-07-08 |
The Upjohn Company |
Therapeutic formulations with bimodal release characteristics
|
|
GB8518301D0
(en)
*
|
1985-07-19 |
1985-08-29 |
Fujisawa Pharmaceutical Co |
Hydrodynamically explosive systems
|
|
GB2181053B
(en)
*
|
1985-10-01 |
1990-05-23 |
Sandoz Ltd |
Pharmaceutical formulations with controlled release of the active substance
|
|
HU197201B
(en)
*
|
1985-10-01 |
1989-03-28 |
Sandoz Ag |
Process for producing oral pharmaceutical compositions of controlled solubility of the active components
|
|
IT1187750B
(it)
*
|
1985-10-15 |
1987-12-23 |
Eurand Spa |
Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
|
|
US4734285A
(en)
*
|
1985-10-28 |
1988-03-29 |
The Dow Chemical Company |
Sustained release compositions
|
|
US4704285A
(en)
*
|
1985-11-18 |
1987-11-03 |
The Dow Chemical Company |
Sustained release compositions comprising hydroxypropyl cellulose ethers
|
|
IE63321B1
(en)
*
|
1986-02-03 |
1995-04-05 |
Elan Corp Plc |
Drug delivery system
|
|
GB2186485B
(en)
*
|
1986-02-13 |
1988-09-07 |
Ethical Pharma Ltd |
Slow release formulation
|
|
IT1191674B
(it)
*
|
1986-03-07 |
1988-03-23 |
Eurand Spa |
Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
|
|
US4662880A
(en)
*
|
1986-03-14 |
1987-05-05 |
Alza Corporation |
Pseudoephedrine, brompheniramine therapy
|
|
GB8608080D0
(en)
*
|
1986-04-02 |
1986-05-08 |
Fujisawa Pharmaceutical Co |
Solid dispersion composition
|
|
US4855143A
(en)
*
|
1986-04-04 |
1989-08-08 |
Hans Lowey |
Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
|
|
US4775535A
(en)
*
|
1986-04-04 |
1988-10-04 |
Hans Lowey |
Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
|
|
US4780320A
(en)
*
|
1986-04-29 |
1988-10-25 |
Pharmetrix Corp. |
Controlled release drug delivery system for the periodontal pocket
|
|
JPS62286925A
(ja)
*
|
1986-06-06 |
1987-12-12 |
Terumo Corp |
水酸化アルミニウムゲルを含有する外用薬組成物
|
|
ATE107857T1
(de)
*
|
1986-06-10 |
1994-07-15 |
Euro Celtique Sa |
Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
|
|
NZ220599A
(en)
*
|
1986-06-16 |
1990-10-26 |
Merck & Co Inc |
Controlled release oral dosage formulation of carbidopa and levodopa
|
|
US4832957A
(en)
*
|
1987-12-11 |
1989-05-23 |
Merck & Co., Inc. |
Controlled release combination of carbidopa/levodopa
|
|
JPS6310702A
(ja)
*
|
1986-07-01 |
1988-01-18 |
Ube Ind Ltd |
徐放化製剤の製造方法
|
|
US4859467A
(en)
*
|
1986-09-25 |
1989-08-22 |
Colgate-Palmotive Company |
Sustained release fluoride composition
|
|
US4861590A
(en)
*
|
1986-09-25 |
1989-08-29 |
Colgate-Palmolive Company |
Sustained release fluoride and calcium composition
|
|
US4851233A
(en)
*
|
1986-10-06 |
1989-07-25 |
Warner-Lambert Company |
Sustained release formulations
|
|
DE3639073A1
(de)
*
|
1986-11-14 |
1988-05-26 |
Klinge Co Chem Pharm Fab |
Feste arzneizubereitungen und verfahren zu ihrer herstellung
|
|
US4752470A
(en)
*
|
1986-11-24 |
1988-06-21 |
Mehta Atul M |
Controlled release indomethacin
|
|
US4822629A
(en)
*
|
1986-12-12 |
1989-04-18 |
Norwich Eaton Pharmaceuticals, Inc. |
Azumolene dosage form
|
|
US4869908A
(en)
*
|
1987-01-09 |
1989-09-26 |
K.V. Pharmaceutical Co. |
Fibre formulations
|
|
US5015479A
(en)
*
|
1987-02-02 |
1991-05-14 |
Seamus Mulligan |
Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
|
|
US4851232A
(en)
*
|
1987-02-13 |
1989-07-25 |
Alza Corporation |
Drug delivery system with means for obtaining desirable in vivo release rate pattern
|
|
US4810502A
(en)
*
|
1987-02-27 |
1989-03-07 |
Alza Corporation |
Pseudoephedrine brompheniramine therapy
|
|
US4915952A
(en)
*
|
1987-02-27 |
1990-04-10 |
Alza Corporation |
Composition comprising drug, HPC, HPMC and PEO
|
|
US5023076A
(en)
*
|
1987-02-27 |
1991-06-11 |
Alza Corporation |
Lamina comprising carboxyvinyl polymer
|
|
DE3887179T2
(de)
*
|
1987-03-02 |
1994-06-16 |
Brocades Pharma Bv |
Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
|
|
US4789549A
(en)
*
|
1987-03-09 |
1988-12-06 |
Warner-Lambert Company |
Sustained release dosage forms
|
|
US4786503A
(en)
*
|
1987-04-06 |
1988-11-22 |
Alza Corporation |
Dosage form comprising parallel lamine
|
|
US5500228A
(en)
*
|
1987-05-26 |
1996-03-19 |
American Cyanamid Company |
Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
|
|
US6645504B1
(en)
*
|
1987-06-24 |
2003-11-11 |
Autoimmune Inc. |
Bystander suppression of type I diabetes by oral administration of glucagon
|
|
EP0297866A3
(en)
*
|
1987-07-01 |
1989-12-13 |
The Boots Company PLC |
Therapeutic agents
|
|
FR2618073B1
(fr)
*
|
1987-07-16 |
1990-09-07 |
Pf Medicament |
Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
|
|
IE60311B1
(en)
*
|
1987-09-24 |
1994-06-29 |
American Home Prod |
Sustained release etodolac
|
|
US4837030A
(en)
*
|
1987-10-06 |
1989-06-06 |
American Cyanamid Company |
Novel controlled release formulations of tetracycline compounds
|
|
US4871731A
(en)
*
|
1987-10-07 |
1989-10-03 |
Marion Laboratories, Inc. |
Captopril and diltiazem composition and the like
|
|
IE64726B1
(en)
*
|
1987-11-20 |
1995-08-23 |
Elan Corp Plc |
Pharmaceutical formulations for preventing drug tolerance
|
|
US4983398A
(en)
*
|
1987-12-21 |
1991-01-08 |
Forest Laboratories, Inc. |
Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
|
|
GB8802391D0
(en)
*
|
1988-02-03 |
1988-03-02 |
Ddsa Pharmaceuticals Ltd |
Medicinal formulations
|
|
US4931285A
(en)
*
|
1988-04-28 |
1990-06-05 |
Alza Corporation |
Aqueous based pharmaceutical coating composition for dosage forms
|
|
US5024842A
(en)
*
|
1988-04-28 |
1991-06-18 |
Alza Corporation |
Annealed coats
|
|
US5160743A
(en)
*
|
1988-04-28 |
1992-11-03 |
Alza Corporation |
Annealed composition for pharmaceutically acceptable drug
|
|
US5096714A
(en)
*
|
1988-06-28 |
1992-03-17 |
Hauser-Kuhrts, Inc. |
Prolonged release drug tablet formulations
|
|
IT1229203B
(it)
*
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5268181A
(en)
*
|
1989-04-13 |
1993-12-07 |
Upsher-Smith Laboratories, Inc. |
Method of using niacin to control nocturnal cholesterol synthesis
|
|
US5126145A
(en)
*
|
1989-04-13 |
1992-06-30 |
Upsher Smith Laboratories Inc |
Controlled release tablet containing water soluble medicament
|
|
GB8913889D0
(en)
*
|
1989-06-16 |
1989-08-02 |
May & Baker Ltd |
New compositions of matter
|
|
EP0489096B1
(en)
*
|
1989-08-25 |
1995-11-15 |
BIOGLAN IRELAND (R & D) LIMITED |
Pharmaceutical compositions and a device for administering the same
|
|
US5198228A
(en)
*
|
1989-09-14 |
1993-03-30 |
Hoechst-Roussel Pharmaceuticals Inc. |
Direct dry compressible acetaminophen tablet
|
|
US5037658A
(en)
*
|
1989-09-14 |
1991-08-06 |
Hoechst-Roussel Pharmaceuticals, Inc. |
Direct dry compressible acetaminophen composition
|
|
US5130140A
(en)
*
|
1989-09-14 |
1992-07-14 |
Hoeschst-Roussel Pharmaceuticals Inc. |
Method of making direct dry compressible acetaminophen composition
|
|
US5476668A
(en)
*
|
1990-08-24 |
1995-12-19 |
Shin-Etsu Chemical Co., Ltd. |
Base for film-coating pharmaceuticals and method for preparing same
|
|
SE9003904D0
(sv)
*
|
1990-12-07 |
1990-12-07 |
Astra Ab |
Method for the manufacture of a pharmaceutical dosage form
|
|
US5223248A
(en)
*
|
1991-02-11 |
1993-06-29 |
The Research Foundation Of State University Of New York |
Non-antibacterial tetracycline compositions possessing antiplaque properties
|
|
US5770588A
(en)
*
|
1991-02-11 |
1998-06-23 |
The Research Foundation Of State University Of New York |
Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
|
|
US5204116A
(en)
*
|
1991-05-01 |
1993-04-20 |
Alza Corporation |
Dosage form providing immediate therapy followed by prolonged therapy
|
|
CA2067975C
(en)
*
|
1991-05-20 |
2003-01-14 |
Cynthia M. Blase |
Buffered matrix aspirin tablet
|
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
|
US5407686A
(en)
*
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
|
NL9102142A
(nl)
|
1991-12-20 |
1993-07-16 |
Dagra Pharma Bv |
Zetpillen met vertraagde afgifte en werkwijze voor de bereiding daarvan.
|
|
NO924985L
(no)
*
|
1991-12-30 |
1993-07-01 |
Akzo Nv |
Thyroaktiv blanding med vedvarende frigjoering
|
|
US5700485A
(en)
*
|
1992-09-10 |
1997-12-23 |
Children's Medical Center Corporation |
Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
|
|
US5922340A
(en)
*
|
1992-09-10 |
1999-07-13 |
Children's Medical Center Corporation |
High load formulations and methods for providing prolonged local anesthesia
|
|
ES2170074T3
(es)
*
|
1992-09-10 |
2002-08-01 |
Childrens Medical Center |
Matrices de polimero biodegradables para la liberacion prolongada de agentes anestesicos locales.
|
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
|
IL109460A
(en)
|
1993-05-10 |
1998-03-10 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
|
CN1071570C
(zh)
*
|
1993-06-14 |
2001-09-26 |
詹森药业有限公司 |
阿司咪唑和假麻黄碱的缓释薄膜包衣片
|
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
|
US20060263428A1
(en)
*
|
1993-09-20 |
2006-11-23 |
Eugenio Cefali |
Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
|
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
|
US6129930A
(en)
*
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
|
US5484607A
(en)
*
|
1993-10-13 |
1996-01-16 |
Horacek; H. Joseph |
Extended release clonidine formulation
|
|
EP0724441A1
(en)
*
|
1993-10-19 |
1996-08-07 |
The Procter & Gamble Company |
Picosulphate dosage form
|
|
US5451409A
(en)
*
|
1993-11-22 |
1995-09-19 |
Rencher; William F. |
Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
|
|
US5891471A
(en)
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
|
KR100354702B1
(ko)
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
|
HUT71408A
(en)
*
|
1994-01-14 |
1995-11-28 |
Egyt Gyogyszervegyeszeti Gyar |
Pharmaceutical compositions containing papaverine for use to treatment of diseases related to glutamaterg neurotransmission
|
|
US5419917A
(en)
†
|
1994-02-14 |
1995-05-30 |
Andrx Pharmaceuticals, Inc. |
Controlled release hydrogel formulation
|
|
US5843480A
(en)
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
|
US5478572A
(en)
*
|
1994-09-06 |
1995-12-26 |
Bristol-Myers Squibb Co. |
Gepirone dosage form
|
|
US6239172B1
(en)
*
|
1997-04-10 |
2001-05-29 |
Nitrosystems, Inc. |
Formulations for treating disease and methods of using same
|
|
US6425881B1
(en)
*
|
1994-10-05 |
2002-07-30 |
Nitrosystems, Inc. |
Therapeutic mixture useful in inhibiting lesion formation after vascular injury
|
|
US5968983A
(en)
*
|
1994-10-05 |
1999-10-19 |
Nitrosystems, Inc |
Method and formulation for treating vascular disease
|
|
US20110196039A9
(en)
*
|
1994-10-05 |
2011-08-11 |
Kaesemeyer Wayne H |
Controlled release arginine formulations
|
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
|
US5728402A
(en)
*
|
1994-11-16 |
1998-03-17 |
Andrx Pharmaceuticals Inc. |
Controlled release formulation of captopril or a prodrug of captopril
|
|
US6103263A
(en)
*
|
1994-11-17 |
2000-08-15 |
Andrx Pharmaceuticals, Inc. |
Delayed pulse release hydrogel matrix tablet
|
|
US5558879A
(en)
*
|
1995-04-28 |
1996-09-24 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
|
|
US5736159A
(en)
*
|
1995-04-28 |
1998-04-07 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
|
|
DE69632569T2
(de)
*
|
1995-06-09 |
2005-08-18 |
Euroceltique S.A. |
Formulierungen und verfahren für eine verlängerte lokalanästhesie
|
|
US5614207A
(en)
*
|
1995-06-30 |
1997-03-25 |
Mcneil-Ppc, Inc. |
Dry mouth lozenge
|
|
WO1997004752A1
(en)
*
|
1995-07-26 |
1997-02-13 |
Duramed Pharmaceuticals, Inc. |
Pharmaceutical compositions of conjugated estrogens and methods for their use
|
|
MXPA98003802A
(es)
*
|
1995-11-14 |
2005-04-29 |
Abbott Gmbh & Co Kg |
Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.
|
|
US6274171B1
(en)
|
1996-03-25 |
2001-08-14 |
American Home Products Corporation |
Extended release formulation of venlafaxine hydrochloride
|
|
PE57198A1
(es)
*
|
1996-03-25 |
1998-10-10 |
American Home Prod |
Formula de liberacion prolongada
|
|
US20030215507A1
(en)
*
|
1996-03-25 |
2003-11-20 |
Wyeth |
Extended release formulation
|
|
US20060073201A1
(en)
*
|
1996-03-25 |
2006-04-06 |
Wyeth |
Extended release formulation
|
|
US5948437A
(en)
*
|
1996-05-23 |
1999-09-07 |
Zeneca Limited |
Pharmaceutical compositions using thiazepine
|
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
|
AU733867B2
(en)
|
1996-06-24 |
2001-05-31 |
Euro-Celtique S.A. |
Methods for providing safe local anesthesia
|
|
US6046187A
(en)
*
|
1996-09-16 |
2000-04-04 |
Children's Medical Center Corporation |
Formulations and methods for providing prolonged local anesthesia
|
|
WO1998029095A2
(en)
*
|
1997-01-03 |
1998-07-09 |
Elan Corporation, Plc |
Sustained release cisapride mini-tablet formulation
|
|
US6004932A
(en)
*
|
1997-03-06 |
1999-12-21 |
Iowa State University Research Foundation, Inc. |
Use of glucagon as a metabolic conditioner for dairy cows and other ruminants
|
|
US7179486B1
(en)
|
1997-04-01 |
2007-02-20 |
Nostrum Pharmaceuticals, Inc. |
Process for preparing sustained release tablets
|
|
CA2216215A1
(en)
*
|
1997-04-05 |
1998-10-05 |
Isa Odidi |
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
|
US6010718A
(en)
*
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
|
US20050064033A1
(en)
*
|
1997-04-11 |
2005-03-24 |
Notario Gerard F. |
Extended release formulations of erythromycin derivatives
|
|
US6551616B1
(en)
*
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
|
US6210710B1
(en)
|
1997-04-28 |
2001-04-03 |
Hercules Incorporated |
Sustained release polymer blend for pharmaceutical applications
|
|
KR100367144B1
(ko)
|
1997-07-02 |
2003-01-14 |
유로-셀티크 소시에떼 아노뉨 |
관절과 체강(ｂｏｄｙ ｓｐａｃｅ)내에서 연장된 마취
|
|
US5895663A
(en)
*
|
1997-07-31 |
1999-04-20 |
L. Perrigo Company |
Pseudoephedrine hydrochloride extended-release tablets
|
|
IN186245B
(es)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
|
ZA989356B
(en)
*
|
1997-10-16 |
1998-11-16 |
Isis Pharma Gmbh |
Pharmaceutical preparations
|
|
US5948440A
(en)
*
|
1997-12-17 |
1999-09-07 |
Ranbaxy Laboratories Limited |
Modified release matrix formulation of cefaclor and cephalexin
|
|
AU736951C
(en)
|
1998-03-19 |
2003-02-20 |
Bristol-Myers Squibb Company |
Biphasic controlled release delivery system for high solubility pharmaceuticals and method
|
|
US6099859A
(en)
*
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
|
US20030118645A1
(en)
*
|
1998-04-29 |
2003-06-26 |
Pather S. Indiran |
Pharmaceutical compositions for rectal and vaginal administration
|
|
US6043259A
(en)
*
|
1998-07-09 |
2000-03-28 |
Medicure Inc. |
Treatment of cardiovascular and related pathologies
|
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
|
US6106862A
(en)
*
|
1998-08-13 |
2000-08-22 |
Andrx Corporation |
Once daily analgesic tablet
|
|
US6214381B1
(en)
|
1998-09-08 |
2001-04-10 |
Effcon, Inc. |
Methazolamide composition and method of use
|
|
DE19842753A1
(de)
*
|
1998-09-18 |
2000-03-23 |
Bayer Ag |
Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
|
|
US20020169145A1
(en)
*
|
1998-10-14 |
2002-11-14 |
Rajen Shah |
Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
|
|
WO2000033818A1
(en)
|
1998-12-11 |
2000-06-15 |
Nostrum Pharmaceuticals, Inc. |
Sustained release tablet containing hydrocolloid and cellulose ether
|
|
US6528090B2
(en)
|
1998-12-18 |
2003-03-04 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US6511678B2
(en)
|
1998-12-18 |
2003-01-28 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US6419953B1
(en)
*
|
1998-12-18 |
2002-07-16 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US20020025341A1
(en)
*
|
1998-12-18 |
2002-02-28 |
Yihong Qiu |
Controlled release formulation of divalproex sodium
|
|
US6713086B2
(en)
|
1998-12-18 |
2004-03-30 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US6150410A
(en)
*
|
1999-02-04 |
2000-11-21 |
Abbott Laboratories |
pH independent extended release pharmaceutical formulation
|
|
ATE306489T1
(de)
|
1999-03-08 |
2005-10-15 |
Medicure Inc |
Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
|
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
|
AU5840200A
(en)
*
|
1999-07-13 |
2001-01-30 |
Medicure Inc. |
Treatment of diabetes and related pathologies
|
|
WO2001013901A2
(en)
*
|
1999-08-20 |
2001-03-01 |
Ferrosan A/S |
A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
|
|
WO2001013900A2
(en)
|
1999-08-24 |
2001-03-01 |
Medicure International Inc. |
Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
|
|
US7771746B2
(en)
*
|
1999-12-03 |
2010-08-10 |
Polichem Sa |
Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
|
|
US20050037073A1
(en)
*
|
2000-01-13 |
2005-02-17 |
Alpharx Inc. |
Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
|
|
US6627223B2
(en)
*
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
|
US6544555B2
(en)
*
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
US6565882B2
(en)
*
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
|
US7442689B2
(en)
*
|
2000-02-29 |
2008-10-28 |
Medicure International Inc. |
Cardioprotective phosphonates and malonates
|
|
DE60110054T2
(de)
|
2000-02-29 |
2006-03-09 |
Medicure International Inc. |
Cardioprotektive phosphonate
|
|
US6586414B2
(en)
|
2000-03-28 |
2003-07-01 |
Medicure International Inc. |
Treatment of cerebrovascular disease
|
|
US6635277B2
(en)
|
2000-04-12 |
2003-10-21 |
Wockhardt Limited |
Composition for pulsatile delivery of diltiazem and process of manufacture
|
|
US6242003B1
(en)
*
|
2000-04-13 |
2001-06-05 |
Novartis Ag |
Organic compounds
|
|
AR030557A1
(es)
*
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
Una tableta en multicapa de liberacion controlada y metodo de tratamiento
|
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
|
DE10031043A1
(de)
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
|
US6897228B2
(en)
*
|
2000-07-07 |
2005-05-24 |
Medicure International Inc. |
Pyridoxine and pyridoxal analogues: new uses
|
|
US6548519B1
(en)
|
2001-07-06 |
2003-04-15 |
Medicure International Inc. |
Pyridoxine and pyridoxal analogues: novel uses
|
|
NZ523815A
(en)
|
2000-07-07 |
2004-07-30 |
Medicure Int Inc |
Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
|
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
|
WO2002036077A2
(en)
*
|
2000-11-06 |
2002-05-10 |
Andrx Pharmaceuticals, Inc. |
Once a day antihistamine and decongestant formulation
|
|
DE60140141D1
(de)
*
|
2000-11-14 |
2009-11-19 |
Vital Health Sciences Pty Ltd |
Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten
|
|
AUPR549901A0
(en)
*
|
2001-06-06 |
2001-07-12 |
Vital Health Sciences Pty Ltd |
Topical formulation containing tocopheryl phosphates
|
|
WO2002051402A1
(en)
*
|
2000-12-22 |
2002-07-04 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
WO2002058670A1
(en)
*
|
2001-01-25 |
2002-08-01 |
Euroceltique S.A. |
Local anesthetic, and method of use
|
|
US20020103110A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Spitzer A. Robert |
System and method for rectal administration of medication for treatment of migraines
|
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
|
BR0207297A
(pt)
*
|
2001-02-15 |
2005-04-19 |
King Pharmaceuticals Inc |
Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
|
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
|
US20040121988A1
(en)
*
|
2001-03-28 |
2004-06-24 |
Medicure International Inc. |
Treatment of cerebrovascular disease
|
|
US20060127474A1
(en)
*
|
2001-04-11 |
2006-06-15 |
Oskar Kalb |
Pharmaceutical compositions comprising fluvastatin
|
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
|
GB0118300D0
(en)
*
|
2001-07-26 |
2001-09-19 |
Cortendo Ab |
Formulations
|
|
CN1547475B
(zh)
*
|
2001-07-27 |
2010-12-15 |
生命健康科学有限公司 |
含电子转移试剂的磷酸酯衍生物的皮肤制剂
|
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
|
US7101569B2
(en)
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
|
US20030180356A1
(en)
*
|
2001-10-29 |
2003-09-25 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
|
BR0215102A
(pt)
*
|
2001-12-13 |
2004-11-03 |
Vital Health Sciences Pty Ltd |
Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
|
|
US20030133982A1
(en)
*
|
2001-12-20 |
2003-07-17 |
Heimlich John M. |
Zero-order sustained release dosage forms and method of making same
|
|
US20030162769A1
(en)
*
|
2002-02-26 |
2003-08-28 |
Easterling W. Jerry |
Composition and method for treating vulvodynia
|
|
US20050176782A1
(en)
*
|
2002-02-26 |
2005-08-11 |
Easterling W. J. |
Medicament and method for treating vulodynia
|
|
BR0311642A
(pt)
*
|
2002-06-07 |
2005-03-01 |
Ranbaxy Lab Ltd |
Formulação de divalproex de sódio de liberação aumentada
|
|
AU2003245504A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Andrx Corporation |
Pharmaceutical compositions for drugs having ph-dependentsolubility
|
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
|
US20040029959A1
(en)
*
|
2002-08-08 |
2004-02-12 |
John Devane |
Isosorbide mononitrate compositions and methods of their use
|
|
AU2002950713A0
(en)
*
|
2002-08-09 |
2002-09-12 |
Vital Health Sciences Pty Ltd |
Carrier
|
|
WO2004028507A1
(en)
*
|
2002-09-24 |
2004-04-08 |
Akzo Nobel N.V. |
Method to improve pharmaceutical tablets having a matrix of cellulose ether
|
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
|
US8092831B2
(en)
*
|
2002-11-08 |
2012-01-10 |
Andrx Pharmaceuticals, Llc |
Antihistamine and decongestant system
|
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
|
ATE534384T1
(de)
*
|
2003-01-17 |
2011-12-15 |
Vital Health Sciences Pty Ltd |
Verbindungen mit proliferationshemmenden eigenschaften
|
|
SE0302947D0
(sv)
*
|
2003-01-24 |
2003-11-07 |
Magle Ab |
A composition material for transmucosal delivery
|
|
US20040156893A1
(en)
*
|
2003-02-11 |
2004-08-12 |
Irwin Klein |
Method for treating hypothyroidism
|
|
US20040186077A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Medicure International Inc. |
Novel heteroaryl phosphonates as cardioprotective agents
|
|
AU2003901815A0
(en)
*
|
2003-04-15 |
2003-05-01 |
Vital Health Sciences Pty Ltd |
Phosphate derivatives
|
|
US20040265323A1
(en)
*
|
2003-05-16 |
2004-12-30 |
Mccormick Beth A. |
Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof
|
|
US20040241234A1
(en)
*
|
2003-06-02 |
2004-12-02 |
Alpharma, Inc. |
Controlled release press-coated formulations of water-soluble active agents
|
|
US7063862B2
(en)
*
|
2003-06-03 |
2006-06-20 |
Biokey, Inc. |
Pharmaceutical composition and method for treating
|
|
PL1638529T3
(pl)
*
|
2003-06-16 |
2017-03-31 |
Andrx Pharmaceuticals, Llc. |
Kompozycja doustna o przedłużonym uwalnianiu
|
|
AU2004258944B2
(en)
*
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
|
AU2004258949B2
(en)
*
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
|
CA2533292C
(en)
*
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
JP2007502296A
(ja)
*
|
2003-08-11 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
ロバストペレット
|
|
US8062672B2
(en)
|
2003-08-12 |
2011-11-22 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
|
WO2005023184A2
(en)
*
|
2003-08-29 |
2005-03-17 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
|
WO2005027877A1
(en)
*
|
2003-09-15 |
2005-03-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
EP1701705A4
(en)
*
|
2003-12-24 |
2007-08-08 |
Advancis Pharmaceutical Corp |
IMPROVED ABSORPTION OF MODIFIED RELEASE DOSAGE FORMS
|
|
WO2005074598A2
(en)
|
2004-01-30 |
2005-08-18 |
Johns Hopkins University |
Nitroxyl progenitor compounds and methods of use
|
|
ATE495730T1
(de)
*
|
2004-03-03 |
2011-02-15 |
Vital Health Sciences Pty Ltd |
Alkaloid-formulierungen
|
|
WO2006004795A2
(en)
|
2004-06-25 |
2006-01-12 |
The Johns Hopkins University |
Angiogenesis inhibitors
|
|
WO2006014427A1
(en)
*
|
2004-07-02 |
2006-02-09 |
Advancis Pharmaceutical Corporation |
Tablet for pulsed delivery
|
|
US20060019929A1
(en)
*
|
2004-07-07 |
2006-01-26 |
Albert Friesen |
Combination therapies employing platelet aggregation drugs
|
|
US20070060549A1
(en)
*
|
2004-08-10 |
2007-03-15 |
Friesen Albert D |
Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
|
|
US8747895B2
(en)
*
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
|
US20060068004A1
(en)
*
|
2004-09-28 |
2006-03-30 |
Aum Nutrapharm Inc. |
Buccal delivery of sea cucumber tablets
|
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
|
EP2417969A1
(en)
|
2004-10-21 |
2012-02-15 |
Aptalis Pharmatech, Inc. |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
|
US7459468B2
(en)
*
|
2004-10-28 |
2008-12-02 |
Medicure International, Inc. |
Aryl sulfonic pyridoxines as antiplatelet agents
|
|
WO2006050598A1
(en)
*
|
2004-10-28 |
2006-05-18 |
Medicure International Inc. |
Dual antiplatelet/anticoagulant pyridoxine analogs
|
|
US20060094749A1
(en)
*
|
2004-10-28 |
2006-05-04 |
Medicure International Inc. |
Substituted pyridoxines as anti-platelet agents
|
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
|
WO2006084082A1
(en)
*
|
2005-02-03 |
2006-08-10 |
Duramed Pharmaceuticals, Inc. |
Compositions of unconjugated estrogens and methods for their use
|
|
JP2008531602A
(ja)
*
|
2005-03-03 |
2008-08-14 |
バイタル ヘルス サイエンシズ プロプライアタリー リミティド |
抗癌特性を有する化合物
|
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
|
MX2007015949A
(es)
*
|
2005-06-17 |
2008-03-07 |
Vital Health Sciences Pty Ltd |
Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
|
|
US20080242642A1
(en)
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
US7541347B2
(en)
|
2007-04-02 |
2009-06-02 |
Medicis Pharmaceutical Coropration |
Minocycline oral dosage forms for the treatment of acne
|
|
US7919483B2
(en)
*
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
|
US20080241235A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
US8722650B1
(en)
|
2005-06-24 |
2014-05-13 |
Medicis Pharmaceutical Corporation |
Extended-release minocycline dosage forms
|
|
US7544373B2
(en)
*
|
2007-04-02 |
2009-06-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
US8252776B2
(en)
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
KR20080047375A
(ko)
|
2005-07-29 |
2008-05-28 |
콘서트 파마슈티컬즈, 인크. |
약제 화합물
|
|
EP1912635B1
(en)
*
|
2005-07-29 |
2014-03-05 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Use of chk2 kinase inhibitors for cancer treatment
|
|
JP2009517411A
(ja)
*
|
2005-11-28 |
2009-04-30 |
メディキュア インターナショナル インコーポレーテッド |
心血管及び関連病状の処置のための調剤
|
|
US8778924B2
(en)
*
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
|
KR20080085839A
(ko)
*
|
2005-12-23 |
2008-09-24 |
바이탈 헬스 사이언시즈 피티와이 리미티드 |
사이토킨 조절 특성을 가진 화합물
|
|
ES2317450T3
(es)
|
2006-01-11 |
2009-04-16 |
Teva Pharmaceutical Industries Ltd. |
Formulacion de liberacion controlada de acido valproico y sus derivados.
|
|
US20070160667A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Nava Shterman |
Controlled release formulation of divalproex sodium
|
|
US8299052B2
(en)
*
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
|
KR101464771B1
(ko)
*
|
2006-06-01 |
2014-11-26 |
머크 샤프 앤드 돔 코포레이션 |
페닐에프린의 지속 방출용 약제학적 조성물
|
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
|
US7538652B2
(en)
*
|
2006-08-29 |
2009-05-26 |
International Business Machines Corporation |
Electrical component tuned by conductive layer deletion
|
|
US20120178810A1
(en)
*
|
2006-09-11 |
2012-07-12 |
Tailor Prakash Boya |
Extended release formulation of an antiepileptic agent
|
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
|
US20080220064A1
(en)
*
|
2006-12-06 |
2008-09-11 |
Ramesh Ketkar Anant |
Extended release matrix formulations of morphine
|
|
US20080160081A1
(en)
*
|
2006-12-11 |
2008-07-03 |
Mutual Pharmaceutical Company, Inc. |
Alfuzosin formulations, methods of making, and methods of use
|
|
ES2531002T3
(es)
|
2007-01-19 |
2015-03-09 |
Xcovery Inc |
Compuestos inhibidores de quinasa
|
|
WO2008102235A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Aurobindo Pharma Limited |
Controlled release formulations of alfuzosin
|
|
US20080241197A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline dosage forms for the treatment of acne
|
|
US20080287418A1
(en)
*
|
2007-05-16 |
2008-11-20 |
Astrazeneca Ab |
Extended Release Compositions and Methods for Their Manufacture
|
|
US20100172991A1
(en)
*
|
2007-06-08 |
2010-07-08 |
Henry Joseph Horacek |
Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
|
|
EP2155170A2
(en)
*
|
2007-06-08 |
2010-02-24 |
Addrenex Pharmaceuticals, Inc. |
Extended release formulation and method of treating adrenergic dysregulation
|
|
KR100836960B1
(ko)
*
|
2007-09-07 |
2008-06-10 |
주식회사 서울제약 |
새로운 나이아신 제어방출형 제제
|
|
PL2303018T3
(pl)
|
2008-06-19 |
2016-06-30 |
Xcovery Holdings Inc |
Podstawione związki pirydazynokarboksyamidowe jako związki będące inhibitorami kinazy
|
|
WO2010017310A1
(en)
|
2008-08-06 |
2010-02-11 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
|
CN102239149B
(zh)
|
2008-10-06 |
2015-05-13 |
约翰·霍普金斯大学 |
喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
|
|
US20100233259A1
(en)
*
|
2008-12-12 |
2010-09-16 |
Pascal Grenier |
Dosage form of ropinirole
|
|
WO2011015953A2
(en)
*
|
2009-08-04 |
2011-02-10 |
Haren Treasurer |
Greater utility with thyroid hormone
|
|
MX350056B
(es)
|
2009-11-03 |
2017-08-25 |
Lupin Ltd |
Formulacion de liberacion modificada de lacosamida.
|
|
NZ600256A
(en)
|
2009-12-02 |
2014-05-30 |
Aptalis Pharma Ltd |
Fexofenadine microcapsules and compositions containing them
|
|
EP2531047A4
(en)
|
2010-02-05 |
2014-03-19 |
Phosphagenics Ltd |
CARRIER WITH AN UNINUTRALIZED TOCOPHERYL PHOSPHATE
|
|
CA2794734C
(en)
|
2010-03-30 |
2017-12-12 |
Phosphagenics Limited |
Transdermal delivery patch
|
|
US9126947B2
(en)
|
2010-10-08 |
2015-09-08 |
Xcovery Holding Company Llc |
Substituted pyridazine carboxamide compounds
|
|
SI2665477T1
(sl)
|
2011-01-20 |
2016-02-29 |
Bionevia Pharmaceuticals Inc. |
Modificirano sproščanje epalrestata ali njegovega derivata in metode za uporabo le-teh
|
|
US9561243B2
(en)
|
2011-03-15 |
2017-02-07 |
Phosphagenics Limited |
Composition comprising non-neutralised tocol phosphate and a vitamin A compound
|
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
|
KR20210156320A
(ko)
|
2013-04-07 |
2021-12-24 |
더 브로드 인스티튜트, 인코퍼레이티드 |
개인맞춤화 신생물 백신을 위한 조성물 및 방법
|
|
EP3006048A4
(en)
*
|
2013-05-31 |
2017-01-18 |
Hisamitsu Pharmaceutical Co., Inc. |
Oral cavity patch
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
ITMI20132065A1
(it)
*
|
2013-12-11 |
2015-06-12 |
Farmatron Ltd |
Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
|
|
AU2014368898B2
(en)
|
2013-12-20 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
CA2936741C
(en)
|
2014-10-31 |
2018-11-06 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
|
EP3297660A2
(en)
|
2015-05-20 |
2018-03-28 |
The Broad Institute Inc. |
Shared neoantigens
|
|
WO2017062997A1
(en)
|
2015-10-09 |
2017-04-13 |
Reckitt Benckiser Llc |
Pharmaceutical formulation
|
|
CN108601732A
(zh)
|
2015-12-09 |
2018-09-28 |
磷肌酸有限公司 |
药物制剂
|
|
EP3397253A1
(en)
|
2015-12-30 |
2018-11-07 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of seizure-related disorders
|
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
|
PL3509591T3
(pl)
|
2016-10-03 |
2022-01-31 |
Highlightll Pharmaceutical (Hainan) Co., Ltd. |
Nowe selektywne inhibitory Jak1 i ich zastosowanie
|
|
WO2018112512A1
(en)
|
2016-12-21 |
2018-06-28 |
Phosphagenics Limited |
Process
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
US9980946B1
(en)
|
2017-01-25 |
2018-05-29 |
Effcon Laboratories, Inc. |
Extended release methazolamide formulation
|
|
US10695309B2
(en)
|
2017-03-31 |
2020-06-30 |
Western New England University |
Sustained-release liothyronine formulations, method of preparation and method of use thereof
|
|
KR20210006353A
(ko)
|
2018-05-04 |
2021-01-18 |
톨리스 |
상피 세포 및 골수 세포 모두를 활성화시키는 tlr3 리간드
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CA3143571A1
(en)
*
|
2019-07-11 |
2021-01-14 |
John Grady BROWN |
Biodegradable material
|
|
AU2021280261A1
(en)
|
2020-05-26 |
2023-01-19 |
Dionis Therapeutics, Inc. |
Nucleic acid artificial mini-proteome libraries
|
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
|
WO2023016321A1
(zh)
|
2021-08-10 |
2023-02-16 |
贝达药业股份有限公司 |
恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
|
|
EP4426829A1
(en)
|
2021-11-01 |
2024-09-11 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|